TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dialectical Behaviour Therapy for Chronically Self-harming Individuals With BPD: Evaluating the Clinical and Cost Effectiveness of a 6-month Treatment
Brief Summary: Standard one-year dialectical behaviour therapy (DBT), which has four components, is an effective treatment for people with borderline personality disorder. However, such DBT programs are in short supply and costly, resulting in long wait lists. In practice, DBT is often reduced in length or intensity. This study will determine whether shorter DBT treatment is clinically effective and cost-effective. In total, 240 self-harming BPD patients will be randomly assigned to receive either 1 year or 6 months of DBT, with follow-up lasting two years. Rates of suicidal and self-harm behaviours, use of health care and general psychological functioning will be examined.


Options:
A: Arm Label: PTSD-EMDR; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: EMDR | Arm Label: Integrated DBT-EMDR; Type: EXPERIMENTAL; Interventions: Behavioral: EMDR, Behavioral: DBT | Intervention Type: BEHAVIORAL; Name: EMDR; Assigned to Arm(s): Integrated DBT-EMDR, PTSD-EMDR | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Integrated DBT-EMDR
B: Arm Label: Mental Training for Surgeons; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Stress Reduction - modified | Arm Label: The Mind of a Surgeon; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active listening and reading | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Stress Reduction - modified; Assigned to Arm(s): Mental Training for Surgeons | Intervention Type: BEHAVIORAL; Name: Active listening and reading; Assigned to Arm(s): The Mind of a Surgeon
C: Arm Label: Nurse led intervention group; Type: EXPERIMENTAL; Interventions: Other: Nurse led intervention group | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Nurse led intervention group; Assigned to Arm(s): Nurse led intervention group
D: Arm Label: Dialectical Behaviour Therapy-6 months; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy-6 months | Arm Label: Dialectical Behaviour Therapy-12 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behaviour Therapy-12 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-6 months; Assigned to Arm(s): Dialectical Behaviour Therapy-6 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-12 months; Assigned to Arm(s): Dialectical Behaviour Therapy-12 months

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dialectical Behaviour Therapy for Chronically Self-harming Individuals With BPD: Evaluating the Clinical and Cost Effectiveness of a 6-month Treatment
Brief Summary: Standard one-year dialectical behaviour therapy (DBT), which has four components, is an effective treatment for people with borderline personality disorder. However, such DBT programs are in short supply and costly, resulting in long wait lists. In practice, DBT is often reduced in length or intensity. This study will determine whether shorter DBT treatment is clinically effective and cost-effective. In total, 240 self-harming BPD patients will be randomly assigned to receive either 1 year or 6 months of DBT, with follow-up lasting two years. Rates of suicidal and self-harm behaviours, use of health care and general psychological functioning will be examined.


Options:
A: Arm Label: Dialectical Behaviour Therapy-6 months; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy-6 months | Arm Label: Dialectical Behaviour Therapy-12 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behaviour Therapy-12 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-6 months; Assigned to Arm(s): Dialectical Behaviour Therapy-6 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-12 months; Assigned to Arm(s): Dialectical Behaviour Therapy-12 months
B: Arm Label: Inpatient Adaptation of DBT; Type: EXPERIMENTAL; Interventions: Behavioral: Inpatient Adaptation of DBT | Arm Label: Outpatient DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: standard outpatient DBT | Intervention Type: BEHAVIORAL; Name: standard outpatient DBT; Assigned to Arm(s): Outpatient DBT | Intervention Type: BEHAVIORAL; Name: Inpatient Adaptation of DBT; Assigned to Arm(s): Inpatient Adaptation of DBT
C: Arm Label: Intensive Group Analytic Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Group Analytic Psychotherapy | Arm Label: Intensive GCBT; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive transdiagnostic cognitive-behavioral group therapy | Arm Label: Wait-list control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive Group Analytic Psychotherapy; Assigned to Arm(s): Intensive Group Analytic Psychotherapy | Intervention Type: BEHAVIORAL; Name: Intensive transdiagnostic cognitive-behavioral group therapy; Assigned to Arm(s): Intensive GCBT
D: Arm Label: Dynamic Cognitive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dynamic Cognitive Intervention Group | Arm Label: No Additional Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dynamic Cognitive Intervention Group; Assigned to Arm(s): Dynamic Cognitive Intervention Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)
Brief Summary: The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.


Options:
A: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2
C: Arm Label: Ipilimumab and Placebo matching Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Other: Placebo matching Nivolumab | Arm Label: Nivolumab and Placebo matching Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Other: Placebo matching Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab and Placebo matching Nivolumab | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab and Placebo matching Ipilimumab | Intervention Type: OTHER; Name: Placebo matching Ipilimumab; Assigned to Arm(s): Nivolumab and Placebo matching Ipilimumab | Intervention Type: OTHER; Name: Placebo matching Nivolumab; Assigned to Arm(s): Ipilimumab and Placebo matching Nivolumab
D: Arm Label: Ipilimumab 10 mg/kg + HDI; Type: EXPERIMENTAL; Interventions: Drug: administration of ipilimumab10mg/kg | Arm Label: Ipilimumab 3mg/kg + HDI; Type: EXPERIMENTAL; Interventions: Drug: administration of ipilimumab 3mg/kg + HDI | Intervention Type: DRUG; Name: administration of ipilimumab10mg/kg; Assigned to Arm(s): Ipilimumab 10 mg/kg + HDI | Intervention Type: DRUG; Name: administration of ipilimumab 3mg/kg + HDI; Assigned to Arm(s): Ipilimumab 3mg/kg + HDI

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)
Brief Summary: The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.


Options:
A: Arm Label: Arm A: Ipilimumab and Dacarbazine; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Dacarbazine | Arm Label: Arm B: Placebo and Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Dacarbazine | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Arm A: Ipilimumab and Dacarbazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm B: Placebo and Dacarbazine | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Arm A: Ipilimumab and Dacarbazine, Arm B: Placebo and Dacarbazine
B: Arm Label: WEX only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Wide Excision | Arm Label: WEX + SLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sentinel Lymph Node Dissection | Arm Label: WEX+SLND+CLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Complete Lymph Node Dissection | Intervention Type: PROCEDURE; Name: Sentinel Lymph Node Dissection; Assigned to Arm(s): WEX + SLND | Intervention Type: PROCEDURE; Name: Complete Lymph Node Dissection; Assigned to Arm(s): WEX+SLND+CLND | Intervention Type: PROCEDURE; Name: Wide Excision; Assigned to Arm(s): WEX only
C: Arm Label: Ipilimumab and Placebo matching Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Other: Placebo matching Nivolumab | Arm Label: Nivolumab and Placebo matching Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Other: Placebo matching Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab and Placebo matching Nivolumab | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab and Placebo matching Ipilimumab | Intervention Type: OTHER; Name: Placebo matching Ipilimumab; Assigned to Arm(s): Nivolumab and Placebo matching Ipilimumab | Intervention Type: OTHER; Name: Placebo matching Nivolumab; Assigned to Arm(s): Ipilimumab and Placebo matching Nivolumab
D: Arm Label: Completion Lymphadenectomy; Type: EXPERIMENTAL; Interventions: Procedure: Completion Lymphadenectomy | Arm Label: Clinical Monitoring (Palpation and node ultrasound); Type: EXPERIMENTAL; Interventions: Procedure: Clinical Monitoring (Palpation and node ultrasound) | Intervention Type: PROCEDURE; Name: Completion Lymphadenectomy; Assigned to Arm(s): Completion Lymphadenectomy | Intervention Type: PROCEDURE; Name: Clinical Monitoring (Palpation and node ultrasound); Assigned to Arm(s): Clinical Monitoring (Palpation and node ultrasound)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Monitoring and Evaluation of the Therapeutic Efficacy and Safety of Pyronaridine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia, an Area of Artemisinin-resistant Falciparum Malaria
Brief Summary: This study is a prospective, single arm, open-labelled clinical trial. The total number subjects will be 145 patients to receive Pyronaridine-artesunate once daily for 3 days. Dosing will be according to the body weight.

All patients will have a blood smear examined daily during the first week by microscopy until parasite clearance (2 consecutive negative slides on two consecutive days; both asexual and sexual stages). A negative blood slide will be defined as parasite count negative per 1000 WBC in two consecutive days. The sample on day 3 will be taken as close as possible to 72h after the initial blood smear.

Participant will follow up for 42 days to assess the drug efficacy and safety (Day 7, 14, 21, 28, 35 and 42).


Options:
A: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate
B: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Arm Label: Artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination; Assigned to Arm(s): Artemether-lumefantrine
C: Arm Label: pyronaridine/artesunate (6:2 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (9:3 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Arm Label: pyronaridine/artesunate (12:4 mg/kg); Type: EXPERIMENTAL; Interventions: Drug: pyronaridine/artesunate | Intervention Type: DRUG; Name: pyronaridine/artesunate; Assigned to Arm(s): pyronaridine/artesunate (12:4 mg/kg), pyronaridine/artesunate (6:2 mg/kg), pyronaridine/artesunate (9:3 mg/kg)
D: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Monitoring and Evaluation of the Therapeutic Efficacy and Safety of Pyronaridine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia, an Area of Artemisinin-resistant Falciparum Malaria
Brief Summary: This study is a prospective, single arm, open-labelled clinical trial. The total number subjects will be 145 patients to receive Pyronaridine-artesunate once daily for 3 days. Dosing will be according to the body weight.

All patients will have a blood smear examined daily during the first week by microscopy until parasite clearance (2 consecutive negative slides on two consecutive days; both asexual and sexual stages). A negative blood slide will be defined as parasite count negative per 1000 WBC in two consecutive days. The sample on day 3 will be taken as close as possible to 72h after the initial blood smear.

Participant will follow up for 42 days to assess the drug efficacy and safety (Day 7, 14, 21, 28, 35 and 42).


Options:
A: Arm Label: Pyramax; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): Pyramax
B: Arm Label: pyronaridine artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): pyronaridine artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): chloroquine
C: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Arm Label: Artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination; Assigned to Arm(s): Artemether-lumefantrine
D: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuroprotection In Patients Undergoing Aortic Valve Replacement
Brief Summary: To evaluate the efficacy and safety of embolic protection devices to reduce ischemic brain injury in patients undergoing surgical aortic valve replacement (AVR).


Options:
A: Arm Label: Noradrenaline; Type: EXPERIMENTAL; Interventions: Other: noradrenaline | Arm Label: Ephedrine chorhydrate; Type: EXPERIMENTAL; Interventions: Other: Ephedryne chorydrate | Intervention Type: OTHER; Name: noradrenaline; Assigned to Arm(s): Noradrenaline | Intervention Type: OTHER; Name: Ephedryne chorydrate; Assigned to Arm(s): Ephedrine chorhydrate
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebos | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone and fludrocortisone and placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and placebos | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone | Intervention Type: DRUG; Name: placebos; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hydrocortisone and fludrocortisone and placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: recombinant human activated protein C and placebos; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: recombinant human activated protein C and hydrocortisone and fludrocortisone; Assigned to Arm(s): 4
C: Arm Label: Embol-X Embolic Protection Device; Type: ACTIVE_COMPARATOR; Interventions: Device: Embol-X Embolic Protection Device | Arm Label: CardioGard Cannula; Type: ACTIVE_COMPARATOR; Interventions: Device: CardioGard Cannula | Arm Label: Standard Cannula; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Embol-X Embolic Protection Device; Assigned to Arm(s): Embol-X Embolic Protection Device | Intervention Type: DEVICE; Name: CardioGard Cannula; Assigned to Arm(s): CardioGard Cannula
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Immediate Effects of Mulligan Mobilization With Movement Technique in Pain, Range of Motion and Physical Function in Patients With Osteoarthritis of the Hip
Brief Summary: The concept of mobilization with movement, also referred to as a Mulligan mobilization, has not been studied in patients with hip osteoarthritis, subsisting questions about the possible effects in this population. The aim of this randomized controlled study is to compare the immediate effects of Mulligan mobilization with movement technique of pain, range of motion and physical function in patients with osteoarthritis of the hip.


Options:
A: Arm Label: Telephone-linked Communication (TLC); Type: EXPERIMENTAL; Interventions: Behavioral: TLC | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: TLC; Assigned to Arm(s): Telephone-linked Communication (TLC)
B: Arm Label: tDCS and EAC sham; Type: ACTIVE_COMPARATOR; Interventions: Other: tDCS and EAC sham | Arm Label: tDCS sham and EAC sham; Type: PLACEBO_COMPARATOR; Interventions: Other: tDCS sham and EAC sham | Arm Label: tDCS sham and EAC; Type: ACTIVE_COMPARATOR; Interventions: Other: tDCS sham and EAC | Arm Label: tDCS and EAC; Type: EXPERIMENTAL; Interventions: Other: tDCS and EAC | Intervention Type: OTHER; Name: tDCS and EAC sham; Assigned to Arm(s): tDCS and EAC sham | Intervention Type: OTHER; Name: tDCS sham and EAC sham; Assigned to Arm(s): tDCS sham and EAC sham | Intervention Type: OTHER; Name: tDCS sham and EAC; Assigned to Arm(s): tDCS sham and EAC | Intervention Type: OTHER; Name: tDCS and EAC; Assigned to Arm(s): tDCS and EAC
C: Arm Label: Real mobilization-with-movement (MWM); Type: EXPERIMENTAL; Interventions: Other: Real mobilization-with-movement (MWM) | Arm Label: Sham mobilization-with-movement (MWM); Type: SHAM_COMPARATOR; Interventions: Other: Sham mobilization-with-movement (MWM) | Intervention Type: OTHER; Name: Real mobilization-with-movement (MWM); Assigned to Arm(s): Real mobilization-with-movement (MWM) | Intervention Type: OTHER; Name: Sham mobilization-with-movement (MWM); Assigned to Arm(s): Sham mobilization-with-movement (MWM)
D: Arm Label: exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Arm Label: exercise + manual therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise, Other: manual therapy | Arm Label: exercise + booster; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: exercise + manual therapy + booster; Type: EXPERIMENTAL; Interventions: Other: Exercise, Other: manual therapy | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): exercise, exercise + booster, exercise + manual therapy, exercise + manual therapy + booster | Intervention Type: OTHER; Name: manual therapy; Assigned to Arm(s): exercise + manual therapy, exercise + manual therapy + booster

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incisional VAC at Cesarean Section for Prevention of Post Operative Wound Complications in the Obese
Brief Summary: To study if incisional vacuum-assisted closure can decrease the risk of infection in cesarean section incisions in the obese compared with standard sterile dressing.


Options:
A: Arm Label: Current Standard; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing | Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Prevena (Negative Pressure Wound Therapy Device) | Intervention Type: DEVICE; Name: Prevena (Negative Pressure Wound Therapy Device); Assigned to Arm(s): Negative Pressure Wound Therapy | Intervention Type: DEVICE; Name: Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing; Assigned to Arm(s): Current Standard
B: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative Pressure Wound Therapy, Other: Usual Care of Surgical Wound | Arm Label: Usual Care of Surgical Wound; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care of Surgical Wound | Intervention Type: DEVICE; Name: Negative Pressure Wound Therapy; Assigned to Arm(s): Negative Pressure Wound Therapy | Intervention Type: OTHER; Name: Usual Care of Surgical Wound; Assigned to Arm(s): Negative Pressure Wound Therapy, Usual Care of Surgical Wound
C: Arm Label: Vacuum-assisted closure (VAC); Type: EXPERIMENTAL; Interventions: Device: Vacuum-assisted closure | Arm Label: Standard sterile dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard sterile dressing | Intervention Type: DEVICE; Name: Vacuum-assisted closure; Assigned to Arm(s): Vacuum-assisted closure (VAC) | Intervention Type: DEVICE; Name: Standard sterile dressing; Assigned to Arm(s): Standard sterile dressing
D: Arm Label: Closed Incision Wound vacuum (Prevena); Type: EXPERIMENTAL; Interventions: Device: Closed incision wound vacuum (Prevena) | Arm Label: Routine Wound Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Closed incision wound vacuum (Prevena); Assigned to Arm(s): Closed Incision Wound vacuum (Prevena)

Answer: C